RT期刊文章SR电子T1的贡献Trans-Synaptic神经元变性视网膜萎缩的女士(P01.161)摩根富林明神经学神经学乔FD Lippincott Williams &威尔金斯SP P01.161 OP P01.161 VO 78是1补充A1尼Ga首页bilondo A1艾伯特Saiz A1 Eloy马丁内斯A1埃琳娜·弗拉加A1莎拉Llufriu A1圣地亚哥Ortiz A1琼Berenguer A1埃琳娜·埃尔南德斯A1玛丽亚赛普维达A1尤兰达布兰科A1弗朗西斯克格劳A1 Bernardo Sanchez-Dalmau A1 Pablo Villoslada年2012 UL //www.ez-admanager.com/content/78/1_Supplement/P01.161.abstract AB目的:评价的贡献后视觉通路损害视网膜萎缩在女士,transynaptic变性的证据。背景几个退化过程导致轴突丧失在女士,被transynaptic变性一个可能的机制,需要进一步验证。设计/方法:我们研究了40名RRMS患者(年龄41岁(21 - 61),28(70%)的女性,疾病持续时间6.8年(8 - 28.8),32例(80%)在治疗,17例(42%)急性视神经炎的历史(AON)]和20名年龄性别匹配的健康对照组(HC)。我们进行了核磁共振研究(3 t)包括sagital T1MPRAGE, DTI和视觉和额叶皮质光谱。视交叉,外侧膝状体核(LGN),视觉皮层(B17和energisk B18)和前额叶皮层(B4)分段T1MPRAGE目前和Freesurfer软件。我们获得了DTI指数(FA, MD, RD和广告)LGN和白质(WM)。高分辨率10月进行了研究使用大脑和视网膜Spectralis 10月卷被斯皮尔曼相关或10月之间的皮尔逊系数和线性回归分析应用措施和大脑核磁共振的措施。结果:时间和papillomacular包(PMB)视网膜神经纤维层厚度(RNFLt)与视觉皮层卷(颞RNFLt: p: 0.045 r: 0.318 B17和p: 0.025, r: 0.354的energisk B18;PMB RNFLt: p: 0.021 r: 0.636 B17和p: 0.03, energisk B18 r: 0.463)。PMB RNFLt也与LGN体积(r p: 0.001: 0.401)。的energisk B18厚度与PMB RNFLt (r p: 0.018: 0.372),不管以前的怡安。乙酰天冬氨酸水平视觉皮层明显与全球RNFLt直系回归模型在控制了年龄,性别,怡安和乙酰天冬氨酸水平额叶皮质(r 2 p: 0.03: 0.52)。Conclusions: Our results support that degeneration of retrogeniculate pathway is specifically correlated with RNFL atrophy, supporting the presence of transynaptic degeneration as a contributor to brain atrophy in MS.Disclosure: Dr. Gabilondo has nothing to disclose. Dr. Saiz has nothing to disclose. Dr. Martínez has nothing to disclose. Dr. Fraga has nothing to disclose. Dr. Llufriu has received personal compensation for activities with Merck Serono and Biogen Idec as a speaker. Dr. Ortiz has nothing to disclose. Dr. Berenguer has nothing to disclose. Dr. Hernández has nothing to disclose. Dr. Sepúlveda has nothing to disclose. Dr. Blanco has nothing to disclose. Dr. Graus has nothing to disclose. Dr. Sánchez-Dalmau has nothing to disclose. Dr. Villoslada has received personal compensation for activities with Roche Diagnostics Corporation, Novartis, MedImmune, Neurotek, Bionure, an Digna Biotech. Dr. Villoslada has received research support from Digna Biotech.Monday, April 23 2012, 14:00 pm-18:30 pm